At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
collagenase clostridium histolyticumdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multicenter, Open-label, Randomized, Parallel-group, Multiple-dose Study to Assess the Effectiveness, Safety and Satisfaction With Collagenase Clostridium Histolyticum Grid Technique Injections of Buttock or Thigh Cellulite With Laxity in Adult Females
In Brief
A Phase 2 clinical trial evaluating collagenase clostridium histolyticum for Edematous Fibrosclerotic Panniculopathy and 2 related conditions. Completed, enrolled 35 participants across 3 sites.
Detailed Summary
This study is designed to investigate the safety and efficacy of collagenase clostridium histolyticum (CCH) for the treatment of mild to moderate edematous fibrosclerotic panniculopathy (cellulite) in participants with moderate to severe dermal laxity in the buttocks or thighs with comparison between two (2) different CCH injection techniques.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartOct 2020
First PostedOct 2020
Primary CompletionAug 2021
Study CompletionSep 2021
TodayJul 2026
First PostedOct 8, 2020
Enrollment StartOct 1, 2020
Primary CompletionAug 30, 2021
Study CompletionSep 24, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.7 years ago
Interventions
collagenase clostridium histolyticumdrug
Delivered via uniform grid injection techniques.